Search Results

You are looking at 141 - 150 of 384 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Breast Cancer, Version 1.2016

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead, and Rashmi Kumar

letrozole alone group included neutropenia (54% vs 1%) and leukopenia (19% vs 0%). Based on this study, the FDA approved palbociclib in combination with letrozole for the treatment of postmenopausal women with ER-positive, HER2-negative advanced breast

Full access

Emerging Therapy for the Treatment of Mantle Cell Lymphoma

Saurabh Rajguru and Brad S. Kahl

PFS was just 4 months, but the median response duration was 16.6 months, suggesting substantial clinical benefit in patients responding to treatment. The most common grade 3/4 AEs were neutropenia (43%) and thrombocytopenia (27%), with 34% and 31% of

Full access

Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

) The most common grade 1/2 toxicities with FOLFOX were fatigue (58%), nausea (32%), and neutropenia (25%). The most common grade 3 toxicities were diarrhea (4%), fatigue (1%), nausea (1%), and neutropenia (1%). These were managed with dose reductions

Full access

Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience

Seth A. Wander, Hyo S. Han, Mark L. Zangardi, Andrzej Niemierko, Veronica Mariotti, Leslie S.L. Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Avinash Kambadakone, Casey Stein, Maxwell R. Lloyd, Megan Yuen, Laura M. Spring, Dejan Juric, Irene Kuter, Ioannis Sanidas, Beverly Moy, Therese Mulvey, Neelima Vidula, Nicholas J. Dyson, Leif W. Ellisen, Steven Isakoff, Nikhil Wagle, Adam Brufsky, Kevin Kalinsky, Cynthia X. Ma, Joyce O’Shaughnessy, and Aditya Bardia

common toxicities include leukopenia/neutropenia, fatigue, diarrhea (for abemaciclib), and rare instances of QTc prolongation (for ribociclib). 1 Although palbociclib and ribociclib have similar pharmacodynamic and pharmacokinetic properties (with

Full access

Indicators of Clinical Trajectory in Patients With Cancer Who Receive Cardiopulmonary Resuscitation

Sanjay Chawla, Cristina Gutierrez, Prabalini Rajendram, Kenneth Seier, Kay See Tan, Kara Stoudt, Marian Von-Maszewski, Jorge L. Morales-Estrella, Natalie T. Kostelecky, and Louis P. Voigt

days of CPR, time of last cancer intervention, neutropenia, and cancer-related therapies after CPR. Cancer types were divided into solid or hematologic (leukemia, lymphoma, multiple myeloma, or HSCT), whereas subtype classification included

Full access

Systemic Therapy for Small Cell Lung Cancer

Benjamin Levy, Ashish Saxena, and Bryan J. Schneider

%; P =.9). More grade 3/4 adverse events occurred in the ACE arm, including anemia (27% vs 18%; P =.03), neutropenia (90% vs 57%; P <.005), and infection (73% vs 29%; P <.0005), leading to more days of hospitalization and greater intravenous

Full access

Targeted Therapy in Relapsed Classical Hodgkin Lymphoma

Shira Dinner and Ranjana Advani

well tolerated, and grade 3 or higher adverse events included neutropenia (20%), thrombocytopenia (8%), anemia (6%), and peripheral sensory neuropathy (8%). This agent was approved by the FDA in 2011 for patients with R/R HL for whom ASCT failed, for

Full access

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016

Steven M. Horwitz, Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Matthew Lunning, Auayporn Nademanee, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar, and Pierluigi Porcu

common grade 3/4 adverse events included thrombocytopenia (32%), neutropenia (22%), anemia (18%), and mucositis (22%). In September 2009, pralatrexate became the first FDA-approved single agent for the treatment of patients with relapsed or refractory

Full access

Evolving Treatment Strategies for Triple-Negative Breast Cancer

Melinda Telli

treated with docetaxel had significantly higher rates of febrile neutropenia and neuropathy, whereas in patients treated with carboplatin, vomiting appeared to be somewhat more common,” explained Dr. Telli. Furthermore, she said, “disappointingly, there

Full access

Advanced Hormone-Sensitive Breast Cancer: Overcoming Resistance

Ingrid A. Mayer

. Mayer suggested. It is worth noting that, because of its side effect profile (neutropenia, gastrointestinal toxicity), palbociclib may not be the best choice for all patients. Finally, targeting methylation through inhibition of histone deacetylase